Clinical Benefits of Dapagliflozin for T2D Remain Irrespective of Background Therapy - MD Magazine

Dapagliflozin consistently reduced the risk of CV death or HHF, HHF alone, and progression of kidney disease regardless of background use of CV medications, investigators say.

New findings suggest dapagliflozin consistently reduced the risk of cardiovascular (CV) and kidney outcomes regardless of background use of various CV medications in patients with type 2 diabetes (T2… [+3036 chars]

full article...